Related Experiment Videos
[Transformed migraine--chronic daily headache].
Summary
Transformed migraine, a common cause of chronic daily headache, benefits from diagnostic labeling. While dihydroergotamine (DHE) offers short-term relief, medication withdrawal and patient support are crucial for long-term management.
Area of Science:
- Neurology
- Headache Medicine
Context:
- Chronic daily headache (CDH) is a significant clinical challenge.
- The International Headache Society classification system does not address the long-term evolution of headache disorders.
- Transformed migraine is increasingly recognized as a prevalent cause of CDH.
Purpose:
- To advocate for the diagnostic label 'transformed migraine' in patients with CDH and migrainous features.
- To evaluate the efficacy of intravenous dihydroergotamine (DHE) as an acute treatment for transformed migraine.
- To emphasize the importance of non-pharmacological interventions in managing CDH.
Summary:
- The study supports using 'transformed migraine' as a diagnostic label for CDH with migrainous features and a history of migraine.
- Intravenous dihydroergotamine (DHE) was administered to 16 patients with CDH; 10 reported immediate relief, but only four had sustained relief beyond two weeks.
- The authors highlight medication withdrawal, patient education, and support as primary therapeutic strategies, with DHE potentially aiding the withdrawal process.
Impact:
- This research encourages a more patient-centered diagnostic approach to chronic daily headache.
- It underscores the limitations of solely relying on acute pharmacological interventions like DHE for transformed migraine.
- The findings emphasize the critical role of comprehensive management strategies, including behavioral support, for improving long-term outcomes in transformed migraine patients.